Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

May 7, 2026 - 18:47

The arrival of the first generic versions of semaglutide in Canada is being watched closely as a potential turning point for Novo Nordisk's dominance in the global weight-loss and diabetes market. Semaglutide is the active ingredient behind the blockbuster drugs Ozempic and Wegovy, which have generated tens of billions of dollars for the Danish pharmaceutical company. Now, with Canadian regulators approving cheaper copycat versions, analysts say this could be the beginning of a steady decline in Novo Nordisk's international revenue from these products.

The Canadian market is often seen as a test case for broader generic competition. Unlike the United States, where complex patent litigation and regulatory hurdles can delay cheaper alternatives for years, Canada's system has allowed for a faster entry. The new generics are expected to be priced significantly lower than the brand-name drugs, potentially making treatment accessible to more patients but also cutting into Novo Nordisk's profit margins.

For Novo Nordisk, the stakes are enormous. Semaglutide-based drugs account for a massive portion of the company's sales. While the company still holds strong patents in other major markets, the Canadian move sets a precedent. If generic manufacturers can successfully navigate patent challenges in Canada, similar efforts in Europe and other regions may follow. The company has already faced pressure from competitors developing their own weight-loss treatments, but the arrival of generics represents a more direct threat to its core revenue stream. For now, the Canadian launch will serve as a real-world indicator of how quickly and deeply generic competition can erode a pharmaceutical giant's most valuable franchise.